Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes

The systemic vasculitides are a group of multisystem diseases, which can be life and organ threatening. High-dose immunosuppressants are required to control inflammation in vital organs, such as the kidneys, lungs, skin, joints, and eyes. Patients report a range of impacts on their health-related quality of life due to symptoms, irreversible damage, and the adverse effects of medications. The measurement of patient perspectives within clinical studies in vasculitis is essential to capture outcomes of greatest importance to patients. Validated generic, disease-specific and symptom-specific patient-reported outcomes available for use in patients with systemic vasculitis are reviewed here.

[1]  P. Merkel,et al.  Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire , 2018, Annals of the rheumatic diseases.

[2]  R. Moots,et al.  2018 update of the EULAR recommendations for the management of Behçet’s syndrome , 2018, Annals of the rheumatic diseases.

[3]  P. Merkel,et al.  Health-related outcomes of importance to patients with Takayasu's arteritis. , 2018, Clinical and experimental rheumatology.

[4]  J. Farrar,et al.  Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure , 2018, Patient related outcome measures.

[5]  Y. Ben-Shlomo,et al.  Young adults’ perspectives on living with kidney failure: a systematic review and thematic synthesis of qualitative studies , 2018, BMJ Open.

[6]  P. Merkel,et al.  Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016 , 2017, The Journal of Rheumatology.

[7]  R. Black,et al.  A Survey of Glucocorticoid Adverse Effects and Benefits in Rheumatic Diseases: The Patient Perspective , 2017, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  P. Merkel,et al.  Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis , 2017, Rheumatology International.

[9]  P. Merkel,et al.  Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016 , 2017, The Journal of Rheumatology.

[10]  P. Tugwell,et al.  OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis , 2017, The Journal of Rheumatology.

[11]  V. Mohan,et al.  Health-related quality of life variations by sociodemographic factors and chronic conditions in three metropolitan cities of South Asia: the CARRS study , 2017, BMJ Open.

[12]  M. Jadoul,et al.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.

[13]  J. Liddle,et al.  What is the impact of giant cell arteritis on patients’ lives? A UK qualitative study , 2017, BMJ Open.

[14]  M. Galeazzi,et al.  Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study , 2017, Internal and Emergency Medicine.

[15]  H. Blasco,et al.  Quality of life of patients treated for giant cell arteritis: a case-control study , 2017, Clinical Rheumatology.

[16]  Y. Cho,et al.  Association of sleep quality in Behcet disease with disease activity, depression, and quality of life in Korean population , 2017, The Korean journal of internal medicine.

[17]  L. Mouthon,et al.  Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. , 2016, Clinical and experimental rheumatology.

[18]  P. Ravaud,et al.  Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. , 2016, Clinical and experimental rheumatology.

[19]  P. Merkel,et al.  Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12 , 2015, The Journal of Rheumatology.

[20]  P. Tugwell,et al.  Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody–associated Vasculitis Using the OMERACT Process , 2015, The Journal of Rheumatology.

[21]  H. Choi,et al.  Cross-cultural adaptation and validation of the Behcet’s Disease Current Activity Form in Korea , 2015, The Korean journal of internal medicine.

[22]  A. Tincani,et al.  Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. , 2015, Autoimmunity reviews.

[23]  G. Hatemi,et al.  Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. , 2015, The New England journal of medicine.

[24]  H. Petri,et al.  Incidence of Giant Cell Arteritis and Characteristics of Patients: Data‐Driven Analysis of Comorbidities , 2015, Arthritis care & research.

[25]  P. Ravaud,et al.  Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.

[26]  P. Merkel,et al.  Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review , 2014, The Journal of Rheumatology.

[27]  A. Silman,et al.  Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations , 2013, Journal of the Neurological Sciences.

[28]  F. Yıldız,et al.  Impaired quality of life, disability and mental health in Takayasu's arteritis. , 2013, Rheumatology.

[29]  C. Pieper,et al.  Pregnancy Outcomes Among Patients With Vasculitis , 2013, Arthritis care & research.

[30]  L. Fraenkel,et al.  Illness Perceptions and Fatigue in Systemic Vasculitis , 2013, Arthritis care & research.

[31]  I. G. Gül,et al.  Evaluation of sexual function in patients presenting with Behçet’s disease with or without depression , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  G. Hunder,et al.  Clinical features of polymyalgia rheumatica and giant cell arteritis , 2012, Nature Reviews Rheumatology.

[33]  P. Merkel,et al.  Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's) , 2012, Arthritis care & research.

[34]  P. Höglund,et al.  Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. , 2012, Arthritis and rheumatism.

[35]  J. Mason,et al.  Takayasu arteritis: severe consequences of delayed diagnosis. , 2011, QJM : monthly journal of the Association of Physicians.

[36]  P. Merkel,et al.  The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis , 2011, The Journal of Rheumatology.

[37]  P. Merkel,et al.  Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda , 2011, Journal of Rheumatology.

[38]  P. Merkel,et al.  Health‐related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis , 2011, Arthritis care & research.

[39]  A. Sibai,et al.  Cross-cultural adaptation and validation of Behçet's disease quality of life questionnaire , 2011, BMC medical research methodology.

[40]  N. Arden,et al.  Mortality in Wegener's granulomatosis: a bimodal pattern. , 2011, Rheumatology.

[41]  P. Merkel,et al.  Patient‐reported outcome assessment in vasculitis may provide important data and a unique perspective , 2010, Arthritis care & research.

[42]  K. Barraclough,et al.  BSR and BHPR guidelines for the management of giant cell arteritis. , 2010, Rheumatology.

[43]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[44]  D. Reid,et al.  Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. , 2010, Rheumatology.

[45]  J. Mason.  Takayasu arteritis—advances in diagnosis and management , 2010, Nature Reviews Rheumatology.

[46]  M. Melikoğlu,et al.  The relationship between disease activity and depression in patients with Behcet disease and rheumatoid arthritis , 2010, Rheumatology International.

[47]  P. Merkel,et al.  Assessment of damage in vasculitis: expert ratings of damage. , 2009, Rheumatology.

[48]  T. Ergun,et al.  Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[49]  K. Aksu,et al.  Quality of life and its relation with disease severity in Behçet's disease. , 2009, Clinical and experimental rheumatology.

[50]  D. Solmaz,et al.  Quality of life in patients with Takayasu's arteritis is impaired and comparable with rheumatoid arthritis and ankylosing spondylitis patients , 2008, Clinical Rheumatology.

[51]  H. Raspe,et al.  EULAR recommendations for the management of large vessel vasculitis , 2008, Annals of the rheumatic diseases.

[52]  K. Saag,et al.  The epidemiology of glucocorticoid-associated adverse events , 2008, Current opinion in rheumatology.

[53]  Alan Tennant,et al.  The Rasch measurement model in rheumatology: what is it and why use it? When should it be applied, and what should one look for in a Rasch paper? , 2007, Arthritis and rheumatism.

[54]  P. Tugwell,et al.  OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.

[55]  D. Patrick,et al.  Patient-reported outcomes to support medical product labeling claims: FDA perspective. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[56]  A. Flahault,et al.  Corticosteroid‐induced clinical adverse events: frequency, risk factors and patient’s opinion , 2007, The British journal of dermatology.

[57]  H. Bodur,et al.  Quality of life and life satisfaction in patients with Behçet's disease: relationship with disease activity , 2006, Clinical Rheumatology.

[58]  J. Fereday,et al.  Demonstrating Rigor Using Thematic Analysis: A Hybrid Approach of Inductive and Deductive Coding and Theme Development , 2006 .

[59]  Jason W. Osborne,et al.  Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis. , 2005 .

[60]  D. Consonni,et al.  Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. , 2005, Arthritis and rheumatism.

[61]  A. Silman,et al.  Development of the BD-QoL: a quality of life measure specific to Behçet's disease. , 2004, The Journal of rheumatology.

[62]  H. Rubin,et al.  Domains of health-related quality of life important to patients with giant cell arteritis. , 2003, Arthritis and rheumatism.

[63]  D. Scott,et al.  Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. , 2003, Arthritis and rheumatism.

[64]  J. Drennan,et al.  Cognitive interviewing: verbal data in the design and pretesting of questionnaires. , 2003, Journal of advanced nursing.

[65]  M. Kupersmith,et al.  Visual Function and Quality of Life Among Patients with Giant Cell (Temporal) Arteritis , 2001, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[66]  S. Candansayar,et al.  Depression, Anxiety Levels and General Psychological Profile in Behçet’s Disease , 2001, Dermatology.

[67]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.

[68]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[69]  H. Doll,et al.  Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. , 2015, Annals of the rheumatic diseases.

[70]  M. Hotopf,et al.  The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism , 2014 .

[71]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[72]  P. Seo.  Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis , 2010 .

[73]  A. Sidawy,et al.  Quality of life of patients with Takayasu's arteritis. , 2008, Journal of vascular surgery.

[74]  M J Buxton,et al.  Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.